Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00669617 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Indacaterol
DRUG: Salmeterol/fluticasone (50/500 μg)
DRUG: Salbutamol (200 µg)
DRUG: Placebo to Indacaterol
DRUG: Placebo to Salmeterol/fluticasone
DRUG: Placebo to salbutamol

Sponsor

Novartis